A team of Shanghai-based researchers has made a landmark advance in Alzheimer’s disease research, identifying a ‘brake’ gene that can slow the degenerative condition’s progression after developing the world’s first in vivo functional map of regulatory switches in astrocytes, the critical support cells that protect brain neurons. The discovery, which has already been successfully validated in Alzheimer’s mouse models, opens an entirely new pathway for developing life-changing treatments for neurodegenerative disorders.
The collaborative research project, led by scientists from the Center for Excellence in Brain Science and Intelligence Technology at the Chinese Academy of Sciences, Shanghai Sixth People’s Hospital, and biotechnology company Genemagic, was published on April 24, 2026, in the peer-reviewed journal *Science*. Unlike most existing Alzheimer’s therapies that focus on targeting beta-amyloid plaques, this work centers on the understudied role of astrocytes in disease progression, offering a complementary approach that could boost treatment outcomes for patients.
Astrocytes are abundant star-shaped cells in the human brain that work to sustain healthy neuronal function. But when Alzheimer’s develops, these critical support cells become dysfunctional, triggering a chain reaction that speeds up the death of neurons and worsens cognitive decline. For years, researchers have understood that stopping this harmful transformation requires identifying the transcription factors — molecular ‘switches’ that control astrocyte activity — but with more than 1,000 distinct transcription factors in the human body, pinpointing the molecules critical to astrocyte health has remained a major, unaddressed challenge.
To solve this problem, the research team developed an innovative in vivo high-throughput sequencing platform called iGOF-Perturb-seq, which enables large-scale, simultaneous analysis of transcription factor function in living organisms. Using adeno-associated viruses engineered to specifically target astrocytes, the team delivered genetic ‘instruction packages’ holding nearly 1,000 different transcription factors into astrocytes in live mouse brains, with each package tagged with a unique molecular barcode to track its impact. The researchers then used single-cell sequencing technology to analyze close to 400,000 individual astrocytes at once, linking each cell’s functional state to the specific transcription factor it had received. This groundbreaking process allowed the team to assemble the first complete functional map of astrocyte regulatory switches ever created.
“This map is like a treasure map, helping scientists quickly identify candidate master regulators that can prevent astrocytes from becoming dysfunctional,” explained Zhou Haibo, the lead scientist of the study. After screening the map for promising candidates, the team narrowed the list down to 39 potential molecules, and after rigorous testing, identified the transcription factor Ferd3l as the most potent regulator capable of repairing dysfunctional astrocytes.
To confirm the gene’s therapeutic potential, the research team tested Ferd3l in mouse models engineered to develop human Alzheimer’s disease. The team activated the Ferd3l gene in the mice’s astrocytes via intravenous injection, and the treated animals saw a dramatic improvement in their cognitive impairments. In standard cognitive tests including object recognition and maze navigation, treated mice performed nearly as well as healthy control mice.
Further analysis of the results showed that Ferd3l helps dysfunctional astrocytes re-establish healthy, cooperative interactions with both neurons and microglia — the brain’s primary immune cells — restoring functional order to the disrupted cellular environment that characterizes Alzheimer’s, according to Zhang Liansheng, first author of the published study.
The complete functional map of astrocyte regulators will be shared openly with research institutions and pharmaceutical companies across the globe, allowing scientists to use the resource to identify similar ‘brake’ genes and therapeutic targets for a wide range of other neurological conditions, including Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and major depressive disorder. The team also noted that their work creates a shared library of potential new drug targets for neurological diseases, which can be expanded over time to support the development of personalized precision therapies for patients.
The research comes as China has already made progress in expanding Alzheimer’s treatment access: an innovative beta-amyloid targeting therapy launched in 2025 is now covered by supplemental public health insurance in major Chinese cities including Beijing, with clinical data showing sustained patient benefits even after treatment is discontinued following successful plaque clearance.
Zhou noted that moving the discovery from foundational research to real-world clinical applications will be the primary focus of the team’s upcoming work, bringing new hope to millions of people worldwide living with Alzheimer’s and related neurodegenerative conditions.